This diploma thesis deals with selected legal questions regarding artwork in Czech Republic. Author focuses on artwork from copyright and civil legal perspective, specifically author´s rights and copyright and its legal protection (civil, administrative and criminal). It also addresses questions concerning licenses and licensing agreements, relation between artwork and its material object, buying and selling artwork, purchase agreement and other types of contract that artists usually encounter. The aim of this thesis is to identify the current state of legislation in this matter and issues that need to be addressed. Among other methods, author used a comparative method and a research in a form of survey in this thesis.

Master´s thesis titled: “Proposal Optimization of Information System" deals with the processing of contracts and possibilities of eliminate the major problems in the company TOROLA design s.r.o.. Based on analysis of internal and external mediums and the financial analysis, I will put forward changes, which they will be helped to improve of the situation of orders.

One of the most important attribute a cloud service provider (CSP) offers their customers through their cloud services is scalability. Scalability gives customers the ability to vary the amount of capacity when required. A cloud service can be divided in three service layers, Infrastructure-as-a-Service (IaaS), Platform-as-a-Service (PaaS) and Software-as-a-Service (SaaS). Scalability of a certain service depends on software licenses on these layers. When a customer wants to increase the capacity it will be determined by the CSP's licenses bought from its suppliers in advance. If a CSP scales up more than what was agreed on, then there is a risk that the CSP needs to pay a penalty fee to the supplier. If the CSP invests in too many licenses that does not get utilized, then it will be an investment loss. A second challenge with software licensing is when a customer outsources their applications to the CSP’s platform. As each application comes with a set of licenses, there is a certain level of scalability that cannot be exceeded. If a customer wants the CSP scale up more than usual for an application then the customer need to inform the vendors. However, a common misunderstanding is that the customer expects the CSP to notify the vendor. Then there is a risk that the vendor never gets notified and the customer is in danger of paying a penalty fee. This in turn hurts the CSP’s relationship with the customer. The recommendation to the CSP under study is to create a successful customer relationship management (CRM) and a supplier relationship management (SRM). By creating a CRM with the customer will minimize the occurring misunderstandings and highlight the responsibilities when a customer outsources an application to the CSP. By creating a SRM with the supplier will help the CSP to maintain a flexible paying method that they have with a certain supplier. Furthermore, it will set an example to the remaining suppliers to change their inflexible paying method. By achieving a flexible payment method with the suppliers will make it easier for the CSP to find equilibrium between scalability and licenses. / Ett av de viktigaste attributen en molnleverantör (CSP) erbjuder sina kunder genom sina molntjänster är skalbarhet. Skalbarheten ger kunden möjligheten att variera mängden kapacitet efter behov. En molntjänst kan delas in i tre serviceskikter, Infrastruktur-as-a-Service (IaaS), Platform-as-a-Service (PaaS) och Software-as-a-Service (SaaS). Skalbarheten av en viss service beror på mjukvarulicenser på dessa skikt. När en kund vill öka kapaciteten bestäms detta av CSP:s förhandsköpta licenser från sina leverantörer. Om en CSP skalar upp mer än vad som avtalats, finns det en risk att CSP:n måste betala en straffavgift till leverantören. Investerar CSP i alltför många licenser som inte utnyttjas, blir det en investeringsförlust. En annan utmaning med mjukvarulicenser uppstår när en kund lägger ut sina applikationer på CSP:s plattform. Eftersom varje applikation levereras med en uppsättning av licenser, finns det en bestämd nivå av skalbarhet som inte kan överskridas. Om en kund vill att CSP:n ska skala upp mer än vanligt för en applikation, måste kunden informera applikationsförsäljaren själv. Dock sker det en missuppfattning då kunden förväntar sig att CSP:n ska meddela säljaren om detta. Det finns en risk att säljaren aldrig blir informerad och kunden hamnar i stor risk för att betala en straffavgift. Detta i sin tur skadar CSP:s relation med kunden. Rekommendationen till CSP:n är att skapa en framgångsrik kundrelationshantering (CRM) och leverantörrelationshantering (SRM). Genom att skapa en CRM med kunden kan förekommande missförstånd minimeras och belysa ansvarsområden som råder när en kund lägger ut sin applikation hos CSP:n. Genom att skapa en SRM med leverantörerna kommer det att hjälpa CSP:n att upprätthålla en flexibel betalmetod som de har med en viss leverantör. Dessutom kommer det att vara ett föredöme för de övriga leverantörerna att ändra sin icke flexibla betalningsmetod. Genom att uppnå en mer flexibel betalningsmetod med leverantörerna kommer det att bli enklare för en CSP att hitta en balans mellan skalbarhet och licenser.

This thesis examines problems concerning international standard-essential patent licensing disputes within the EU from a private international law perspective. Furthermore, it seeks to analyse the jurisdictional rules which are established by the Brussels Ia Regulation when applied to cross-border SEP licensing disputes. The backdrop for the present study is the system of international standardisation and the licensing of those patents which are essential to the implementation of a technical standard. It is primarily concerned with EU law as it relates to technical standardisation in the field of telecommunications, since it plays a significant role in today’s global information society. As a rule, SEP holders make a commitment to license their essential patents according to terms which are fair, reasonable and non-discriminatory (FRAND). In order to fulfil the aim of the thesis, the legal nature of such a FRAND commitment has been examined, finding that it should be characterised as an enforceable contract for the benefit of third parties. Patent rights have traditionally been thought of as territorial in nature, which raises questions regarding the possibilities for cross-border enforcement, as well as how the rules on jurisdiction should be applied by national courts in the EU when faced with international disputes where the subject matter is considered to be, to an extent, territorially bound. One of the fundamental questions that arise out of this is how, in the context of SEP licensing, the legal framework for SEP disputes affects the application of the jurisdictional rules in cross-border cases. As a consequence of the lack of harmonisation as well as legal regulation and guidance relating to SEP licensing, individual courts in Europe have developed their own distinct approaches and methodologies in SEP disputes. There is a risk that this lack of uniformity leads not only to greater legal uncertainty, but also widespread patent litigation. In particular, recent case law from Germany and the United Kingdom has been influential in creating a precedent that national courts are able to set FRAND licensing terms which are global in scope. This has led to certain courts taking a more active approach in international SEP disputes—even if they concern foreign patents—granting injunctions which in some cases seek to limit the jurisdiction of foreign courts. It seems to follow from this that a ‘race to the courthouse’ is to be expected in SEP disputes, which is further facilitated by the ample room for forum shopping that exists in the Brussels Ia Regulation. Lastly, the thesis also deals, in part, with the new unitary patent system, as well as the Unified Patent Court and the question of how the UPC may come to affect the future of SEP disputes within the EU. Appropriate solutions to the identified problems are discussed, favouring either a concentration of SEP litigation to one forum, or the development of guiding principles so as to increase legal certainty.

yes / Small arms and light weapons can enter the illicit market at many stages in their lifecycle. From manufacture, to sale/export, to import, and then to final end use, States must establish and enforce stringent and comprehensive licensing and monitoring systems to ensure that small arms and light weapons (SALW) remain under legal control. The UN Conference on the Illicit Trade in Small Arms and Light Weapons in All Its Aspects and ensuing follow-up process provide States with important opportunities to analyse and compare how existing systems governing the manufacture and trade in SALW are working. They further provide the context in which best practice can be agreed and implemented internationally, and for the discussion of how future trends and developments in SALW manufacture and transfer can be more effectively brought within State control. To this end, this briefing paper covers two separate but closely related issues. The first section of the report will analyse existing State and regional controls on SALW manufacture and examine how international measures, including the UN Conference, can reinforce such controls. In this regard, the growth of licensed production and co-production agreements is highlighted, together with implications for the development of adequate regulations. The second section examines those systems that are currently in place for the authorisation of SALW transfers and for the certification and monitoring of their ultimate end-use. Recommendations for best practice and implications for the UN Conference process are also discussed.

This thesis examines the perceived importance by two-tiered management of Cooperative Research Centres (CRCs) for managing a range of intellectual property issues. Fifty survey items are presented to the executive directors and commercialization managers of 62 CRCs. The survey items are categorized under four themes: relationships with collaborators, project management; design and implementation of agreements; and specific licensing issues. An analysis of the data, using a series of independent samples t-tests, repeated measures t-tests, chi-square tests for independence or relatedness and goodness of fit, shows a range of results. There are significant differences between executive directors and commercialization managers on a number of issues. There are particular emphases or trends about certain issues for the whole sample of managers. These findings are compared with text analyses of 23 CRC strategic planning documents. This is done in order to explore any similarity, difference or nuance between what the managers say in response to the survey items, compared with what is stated in the codified policies of the CRCs. While there is a high degree of consistency among certain themes between the two sets of findings, the overall analysis points to the need for the CRCs to have a better understanding and practice of commercialization opportunities, especially through the involvement of third party commercial interests. It is argued that accommodating third party commercialization interests involves the application of an important knowledge economy principle that has an important bearing on the future economic viability and competitiveness of the CRCs.

In 2001 the Declaration on the TRIPS Agreement and Public Health (‘Doha Declaration’), affirmed the right of member states of the World Trade Organisation (‘WTO’) to interpret and implement the TRIPS Agreement as supportive of the protection of public health and, in particular, access to medicines. While initially well-received, consternation soon arose over the interpretation of a specific paragraph in the Doha Declaration dealing with compulsory licensing. After a further two years of deliberation, the WTO Decision on the Interpretation of Paragraph 6 (‘Paragraph-6 Decision’) was announced in August 2003 specifying when countries can import drugs produced elsewhere under compulsory licence. With one third of the world's population is still denied access to essential medicines - a figure which rises to over 50 per cent in Asia and Africa - the problems facing the public health community are two-fold. The first is the capacity of developing countries (‘DCs’) actually to use the flexibilities afforded under the TRIPS Agreement, the Doha Declaration, and the Paragraph- 6 Decision amid stark inequalities in health resources and the world trading system as a whole. These include provisions for compulsory licensing, parallel importation, and addressing imbalances in research and development (‘R&D’). The pending ratification of the Paragraph-6 Decision, from an interim solution to a permanent amendment, is accompanied by considerable uncertainty: will the protections be accessible under the system currently proposed? The second problem concerns the undermining of the above hard-won flexibilities by provisions adopted under various bilateral and regional trade agreements. Known as ‘TRIPS-plus’- or ‘WTO-plus’- measures, the level of intellectual property rights (‘IPRs’) rights protection being negotiated and even adopted under other trade agreements are more restrictive as regards public health protection. These two sources of concern have led to an increase in rather than a lessening of tensions between the public health and trade policy communities. The thesis opens with a brief analysis of the interplay between patents and medicines. This includes an overview of the human rights framework and the right of access to medicines as a manifestation of human rights. The historical development of the TRIPS Agreement, its legitimacy, and the effect of the introduction of patents for pharmaceuticals are critically analysed. The terms of the Doha Declaration as it relates to public health, the Paragraph-6 Decision and its system, the December 2005 Amendment, and the progress made to date on the public health protections available under the TRIPS Agreement are reviewed and discussed in detail. The thesis describes how, despite these important clarifications, concerns as to the capacity of DCs to implement specific measures persist. This thesis further addresses the development of compulsory licensing in India and South Africa, and the legal framework for compulsory licensing in these countries. The role of competition law and constraints faced by DCs in implementing the flexibilities offered by the TRIPS Agreement and Doha Declaration are considered before turning to the threat posed by TRIPS-plus measures and calls for their critical reassessment. The thesis considers the role of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG), the WHO Commission on IPRs, Innovation and Public Health (CIPIH), Patent Pools, and international and multilateral donors in access to medicines. The thesis concludes by reviewing potential ways forward to ensure that access to medicines by the poor living in DCs is secured in all trade agreements. / Mercantile Law / LL.D.

In 2001 the Declaration on the TRIPS Agreement and Public Health (‘Doha Declaration’), affirmed the right of member states of the World Trade Organisation (‘WTO’) to interpret and implement the TRIPS Agreement as supportive of the protection of public health and, in particular, access to medicines. While initially well-received, consternation soon arose over the interpretation of a specific paragraph in the Doha Declaration dealing with compulsory licensing. After a further two years of deliberation, the WTO Decision on the Interpretation of Paragraph 6 (‘Paragraph-6 Decision’) was announced in August 2003 specifying when countries can import drugs produced elsewhere under compulsory licence. With one third of the world's population is still denied access to essential medicines - a figure which rises to over 50 per cent in Asia and Africa - the problems facing the public health community are two-fold. The first is the capacity of developing countries (‘DCs’) actually to use the flexibilities afforded under the TRIPS Agreement, the Doha Declaration, and the Paragraph- 6 Decision amid stark inequalities in health resources and the world trading system as a whole. These include provisions for compulsory licensing, parallel importation, and addressing imbalances in research and development (‘R&D’). The pending ratification of the Paragraph-6 Decision, from an interim solution to a permanent amendment, is accompanied by considerable uncertainty: will the protections be accessible under the system currently proposed? The second problem concerns the undermining of the above hard-won flexibilities by provisions adopted under various bilateral and regional trade agreements. Known as ‘TRIPS-plus’- or ‘WTO-plus’- measures, the level of intellectual property rights (‘IPRs’) rights protection being negotiated and even adopted under other trade agreements are more restrictive as regards public health protection. These two sources of concern have led to an increase in rather than a lessening of tensions between the public health and trade policy communities. The thesis opens with a brief analysis of the interplay between patents and medicines. This includes an overview of the human rights framework and the right of access to medicines as a manifestation of human rights. The historical development of the TRIPS Agreement, its legitimacy, and the effect of the introduction of patents for pharmaceuticals are critically analysed. The terms of the Doha Declaration as it relates to public health, the Paragraph-6 Decision and its system, the December 2005 Amendment, and the progress made to date on the public health protections available under the TRIPS Agreement are reviewed and discussed in detail. The thesis describes how, despite these important clarifications, concerns as to the capacity of DCs to implement specific measures persist. This thesis further addresses the development of compulsory licensing in India and South Africa, and the legal framework for compulsory licensing in these countries. The role of competition law and constraints faced by DCs in implementing the flexibilities offered by the TRIPS Agreement and Doha Declaration are considered before turning to the threat posed by TRIPS-plus measures and calls for their critical reassessment. The thesis considers the role of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG), the WHO Commission on IPRs, Innovation and Public Health (CIPIH), Patent Pools, and international and multilateral donors in access to medicines. The thesis concludes by reviewing potential ways forward to ensure that access to medicines by the poor living in DCs is secured in all trade agreements. / Mercantile Law / LL.D.

Kenyan labour laws inadequately protect HIV positive worker. The Constitution of Kenya, 1963, does not prohibit stereotypical attitudes adverse to HIV positive workers and discrimination on the basis of health status. It does not provide for the right to employment, health and health care services, and fails to delimit privacy and dignity rights. Under the Industrial Property Act, 2001, the basis for Government exploitation of patent through compulsory licensing is whimsical and parallel importing is not envisaged. Employers unilaterally draft employment contracts notwithstanding their unequal power relations to employees. The HIV and AIDS Tribunal institutionalises discrimination against HIV positive workers on the basis of the ambiguous ‘inherent job requirements.’ Plausible international labour laws and practices have no place in Kenya unless they are domesticated. SUMMARY This thesis interrogates the Kenyan labour laws and policies to identify their inefficiencies and suggest recommendations for reform. It commences with an analysis of the topical issues associated with the HIV positive worker. It then examines the extent of prevalence and ramifications of HIV/AIDS in Kenya. Subsequently, it studies the efforts made at the international and domestic arena in protecting the HIV positive worker. A comparative analysis is made of the laws protecting the HIV positive worker in a number of countries, namely, South Africa, United States of America and Australia. The thesis draws conclusions and recommends measures on how best to protect the Kenyan HIV positive worker. The labour laws should be amended to prohibit discrimination on the basis of health status, provide for right to affordable medication and work, allow negotiation of employment contracts, list international laws that Kenya ratifies without reservation as a source of law and delimit the concept of ‘inherent requirements of a job.’ The public should be sensitised to embrace HIV positive workers. Once the new Constitution is enacted, it should list socio-economic rights as fundamental rights and reform the office of the ombudsman to deal with complaints against private employers. / (LL.D.)

「被忽視」的熱帶疾病(NTDs)中的寄生蟲疾病(Parasitic Diseases; PDs)除對非洲人群健康之危害甚鉅外，並進而對非洲地區社經體系造成嚴重衝擊與造成巨大的「失能調整人年」損失。由於不易取得治療PDs傳統基本藥物的問題，許多非洲民眾便以其部落社區的傳統治療師所採用的傳統草藥來進行PDs的治療，雖然這些傳統草藥容易取得，但是成分的內容和藥效品質甚或產生嚴重的致命副作用。雖然TRIPS協定第31條和杜哈宣言的第五和第六段對於製藥能力不足或大部分皆無製藥能力的貧窮國家，可以基於「國家緊急危難或其它緊急狀況」的事由，以強制授權方式取得專利藥或較便宜的學名藥以解決造成國家危難的特定公共健康事件，但是國際大藥廠認為無利可圖，不願意花費資金投注於預防或治療此類疾病藥物的相關研發外，高收入的國家為保護其大藥廠的藥物專利，也往往使用一些經濟制裁手段逼迫上述國家就制定國內專利法以保護其藥物專利。雖然經杜哈宣言修正TRIPS協定第31(f)條有關強制授權對外出口的障礙，但是出口國對於強制授權程序與是否能取得政治上和藥廠業者的支持，仍充滿困難。應用「專利池」可以減少交易成本或法律爭議而可調和「強制授權」與解決「權利耗盡」的爭議，有助於解決非洲開發中國家取得專利藥物的困境。PDs造成非洲開發中國家民眾失能等長期痛苦與健康生活損失，類推適用SARS模式，可依TRIPS協定第31條(b)與杜哈宣言第五段(c)將之視為「造成國家緊急危難或其它緊急狀況」的重大公共健康的事由而可行使強制授權。雖然「生醫專利池BVGH」的「非獨家個別授權與免授權費」的操作模式與傳統電信技術專利池不盡相同，但因藥廠不願投入治療PDs的傳統基本藥物存在的副作用與抗藥性的新藥研發，為鼓勵對治療PDs的藥物進行創新研發， BVGH彈性的授權方式與免繳交授權費，將有利於解決開發中國家未來取得新專利藥的困境。除BVGH外，建議結合全球獎勵基金以「激勵拉拔」的方式獎助願意投入治療PDs新藥研發並將專利自願授權給BVGH的藥廠。鑒於全球暖化與最近中東難民潮大量湧進歐洲，罕見的PDs可預期會大量傳播開來，將嚴重衝擊歐洲等先進國家良好的公共衛生體系，而使得「NTDs尤其是PDs不再只是專屬於貧窮國家的疾病，亦將常現於富有的先進國家」。這些NTDs疾病將提供藥廠進行新藥研發的利基，然而在未來可能產生專利池的反競爭問題，導致支配市場獨占性的隱憂值得關注。 / Parasitic diseases (PDs) not only cause the huge health hazards to African populations, but also they further severely impact on African socio-economic system as resulting in huge economic and health losses as assessed by disability adjusted life-years. Since it is not easy for Africans to access the essential medicine to treat PDs, many of them will seek for the help of local healers in tribal communities to treat PDs. Although these traditional herbs are readily available, the content and quality of drug ingredients may even cause serious fatal side effects. Poor countries with insufficiencies or lacks of the pharmaceutical capacities may still access the patented medicines or cheaper generics to solve the national crisis caused by the specific public health events through compulsory licensing (CL) based on "national emergency or the other emergency situations" according to TRIPS Article 31 and Doha Declaration on the fifth and sixth paragraph due to that the large international pharmaceutical companies consider unprofitable, unwilling to spend money to invest on the research and development (R&D) of new drugs for prevention or treatment purpose. Moreover, the high-income countries also tend to exert some of the economic sanctions to force those poor countries to enact national patent law in order to protect drug patents. Furthermore, the mandatory obstacle of exportation authorized by CL from the amended TRIPS Agreement Article 31 (f) by the Doha Declaration has been improved; nevertheless, it is still fraught with difficulties in utilization of CL for the exporting countries because this should be dependent on whether they may actually get the supports from political and the pharmaceutical industry. Application of patent pools model may benefit to reduce transaction costs or legal dispute thus reconciling and resolving issues related to CL as well as doctrine of patent exhaustion and that it is beneficial to help solve dilemma for African countries to access patented drugs. Because Africans severely suffer from disabled caused by PDs thus leading to long-term pain and health life losses, African countries can grant CL as PDs may be regarded as national crisis like SARS causing "national emergency or the other emergency situations" as authorized from TRIPS Agreement Article 31 (f) and Doha Declaration paragraph 5 (c). Although the practice of individual licensing with royalty-free for BVGH is somewhat different from that of traditional patent pools, this licensing practice mode is beneficial to innovation in new drugs R&D to improve the side effects and drug-resistance of traditional essential medicines and help African countries to access patented new drugs in the future. Finally, it is recommended to cooperate with Award Foundation to encourage incentive for pharmaceutical companies which contribute most to new drugs R&D and voluntary licensing to BVGH. Owing to global warming and recent emergence of huge refugees into Europe rare PDs will be obviously spread out thus causing severe impacts on well-established public health system as leading to emergence of PDs in developed countries like Europe. Altogether, such situations definitely provide a good incentive in new drugs R&D for pharmaceutical companies; however, it guarantees concerns on anti-competitive and monopoly issues derived by biomedical pools in the future.